Hanqing is an Investment Director for Merck GHI Fund and is responsible for supporting all areas of digital health. Prior to joining Merck, Hanqing was a technical specialist at Finnegan, Henderson, Farabow, Garrett & Dunner, where her responsibilities included conducting due diligence and freedom to operate analyses in the life sciences industry; drafting patent applications; patent portfolio management; and patent prosecution in jurisdictions around the world. Hanqing also worked in R&D for Quantgene, a start-up focused on the detection of early-stage cancers using liquid biopsies. Hanqing holds a Ph.D. in Biology from the California Institute of Technology, where her research focused on the development of assays for detecting protein-protein interactions, as well as their utilization in the study of the neuromuscular junction in D. melanogaster models.
